Managing Costs in High Risk Obstetrics: The Value of Technology that Improves Diagnostic Accuracy

Maria Lopes*
AMC Health, USA

Introduction

In the USA, about 12.8% of babies (more than half a million a year) are born prematurely. The rate of premature birth has increased by 36% since the early 1980's, [1] and is now responsible for an estimated $26 billion in costs to the American healthcare system annually [2]. Unfortunately, little progress has been made to decrease prevalence in so serious condition.

From a managed care perspective, a premature birth constitutes a potential high cost episode of care and high-risk pregnancies constitute a major category of high-cost for payers. In Medicaid, 27% of all inpatient charges and 68% of all hospital procedures covered by Medicaid [3] are related to pregnancy and although only 10% of pregnancies are considered high risk, they account for 57% of total newborn costs [4]. A recent analysis found that overall, 4% of the Medicaid population was responsible for 48% of program spending in 2001 [5]. These high-cost members translate into highly concentrated spending on only a small fraction of the entire population.

In this paper we will identify ways in which new technology can improve the diagnostic accuracy of pregnancy-related disorders and assist in managing the costs of high risk obstetrics.

High Risk Pregnancy and Preterm Birth

A pregnancy is considered high-risk for a variety of reasons, generally categorized into those of maternal or fetal origin. Prevalent maternal factors include age (younger than age 15, older than age 35); weight (pre-pregnancy weight under 100 lb or obesity), medical comorbidities and a history of complications during previous pregnancies, among others. Prevalent fetal factors include exposure to infection (herpes simplex, viral hepatitis, mumps, rubella, etc.), exposure to addictive substances (cigarette smoking, alcohol intake, and illicit or abused drugs), and exposure to a variety of medications.

Preterm birth is defined as delivery before 37 weeks of gestation. It is the leading cause of neonatal death and infant mortality, often as a result of respiratory distress syndrome due to immature lung development [6]. Babies who survive are also at high risk of neurological disability [7] and can experience further breathing, feeding, digestive, visual, and hearing problems. Observational studies have found that a prior history of preterm birth significantly increases the risk of another in a subsequent pregnancy [8].

Identifying Areas for Improved Management of Preterm Birth

Births that follow spontaneous preterm labor (PTL) and preterm premature rupture of membranes (pPROM) are together designated as spontaneous preterm births. Spontaneous preterm births account for ~70% of all premature deliveries, where the remaining 30% are indicated as a result of maternal or fetal infection [9]. Of those births classified as spontaneous preterm births, 64% are the result of preterm labor (PTL) and 36% are the result of preterm premature rupture of membranes (pPROM).

PTL is defined as the onset of active contractions at a preterm (<37 weeks) gestation. Common symptoms suggestive of PTL include: uterine activity, abdominal discomfort, change in vaginal discharge, bleeding and/or cramping. Traditional evaluation includes uterine activity monitoring and evaluation of the cervix [10]. The exact mechanism(s) of preterm labor is largely unknown, but is believed to include: decidual hemorrhage, (e.g. abruption, mechanical factors such as uterine over-distension from multiple gestation or polyhydramnios), cervical incompetence (e.g. trauma, cone biopsy), uterine distorsion, cervical inflammation, drug abuse, smoking, alcohol consumption, among others [11].

PPROM is defined as spontaneous rupture of the membranes at less than 37 weeks of gestation at least one hour before the onset of contractions. Common symptoms include complaints of leakage in the absence of active labor. Traditional diagnostics methods include nitrazine/pH, ferning, and ultrasound. Indigo carmine intra-amniotic injection may be indicated if status remains questionable after all other methods are performed [12].

The exact mechanism(s) of PPROM is largely unknown, but is believed to include: bacterial production of proteases and phospholipases, host response to blood or bacteria resulting in leukocyte activation and cytokine release, weakness from over distention, strain from preterm uterine activity, direct membrane trauma (cerclage or amniocentesis), or a developmental weak spot [13].

Preterm Labor (PTL) Diagnostic Methods: Improvements and The Associated Cost Impacts

Improved diagnostic methods leading to improved management can directly impact the 70% of spontaneous preterm births caused by both PTL and PPROM. The past decade has seen major developments in the diagnosis of both conditions, the latter of which is now increasingly considered by managed care.

The ability for a clinician to diagnose true PTL has taken significant strides in the past two decades with the advent of the fetal fibronectin (fFN) biomarker test. The presence of fFN in the vagina after the twentieth week is abnormal and may indicate disruption of the attachment of the fetal membranes between the uterine wall and the decidua [14]. Prior to the availability of this assay, discerning true preterm labor from false preterm labor depended on multiple methods that were neither sensitive nor specific enough to accurately predict a time to delivery for the patient presenting with complaints of early...
contractions. These methods consisted of home uterine monitoring and cervical length measurements. While they had good predictive values for obvious cases (i.e., uterine contractions or cervical changes), they did not serve a useful function in predicting time to delivery in the absence of pronounced symptoms.

With the FDA approval of the fFN test (Adeza Biomedical, Sunnyvale, CA) in 1997 [15], this situation changed due to the high negative predictive value (99.5%) of the test for delivery within 14 days [16]. Historically, the suspected PTL patient typically translated into unnecessary home uterine activity monitoring, potential admissions and hospitalization. With the use of the fFN test, however, evaluation of the patient was changed to a screening process that resulted in the clinician’s ability to reduce uncertainty and confidently rule out PTL with a negative result.

Cost-saving implications of this test on the diagnosis of preterm labor can be seen in both the avoidance of unnecessary hospital admissions, as well as unnecessary patient transfers from a medical center of lower trauma level classification to one with a higher trauma level. Joffe et al. [17] reported a savings in hospital admissions costs of $486,000 annually as a result of the fFN test [17] and Giles et al. [18] reported a 90% reduction of transfer costs with the use of the fFN test [18].

Preterm PROM (PPROM) Diagnostic Methods: Improvements and The Associated Cost Impacts

Over the past century, countless approaches have been proposed for the diagnosis of premature or pre-labor rupture of the fetal membranes (PROM) [19,20]. As was the case for PTL, the diagnosis of PROM when symptoms are pronounced (i.e., gross rupture of membranes with obvious fluid leakage) is easy to make. However, in 40-47% of patients presenting with suspicion of ROM, obvious leakage from the cervix cannot be visualized and the diagnosis becomes difficult to confirm or rule out [21,22].

As demonstrated in table 1, standard diagnostic methods, including nitrazine, ferning pooling and ultrasound, alone or in combination with one another, have proven inaccurate in such cases. In the absence of an accurate test to diagnose or rule out ROM, the patient is at a greater risk for not receiving the necessary interventions, including appropriate use of steroids. Failure to implement salutary measures can have both significant medical and financial implications for the payer, the mother and baby, as well as for the hospital and the obstetrician. Conversely, a false positive diagnosis can lead to unnecessary hospitalizations and induction of labor.

As table 1 shows, with the advent of the biomarker test based on the detection of placent al alpha microglobulin-1 (PAMG-1) (marketed as the AmniSure® ROM Test, manufactured by AmniSure® International LLC, Boston, MA), the clinician now has the ability to diagnose ROM with a rapid, non-invasive, highly sensitive and specific test in the 40-47% of ROM cases that are not obvious. PAMG-1 is a decidual protein with very high concentrations in amniotic fluid with extremely low concentrations in background cervico-vaginal secretions.

Significant financial impact results from the use of the PAMG-1 test primarily due to: (i) reductions in costs associated with false diagnoses using traditional methods and (ii) reductions in current spending on ROM diagnosis in non-obvious cases using traditional methods.

Costs of Inaccurate Diagnoses

When used alone, or in combination, traditional methods result in high costs due to their poor accuracy, especially when used on non-obvious cases (Table 2). This leads to important economic considerations surrounding the implications of false diagnoses including (i) costs associated with false negative diagnoses that result in the failure to treat in a timely manner and (ii) costs associated with false positive diagnoses that result in unnecessary admissions and unwarranted induction of labor.

Costs of False Negative Diagnoses

Currently, there are two main treatments used on patients with the diagnosis of PROM: prophylactic antibiotics, to fight infection and prolong latency, and corticosteroids, to help mature the fetal lungs in anticipation of a preterm birth. Table 3 summarizes multiple randomized-controlled trials that have demonstrated that antibiotics have a significant impact on the reduction of various conditions that may result as a consequence of PROM including maternal chorioamnionitis and neonatal infection [37]. Failure to administer antibiotics could result in increased risk of infection that could have otherwise been prevented or treated via the timely administration of antibiotics. By reducing the incidence of these conditions through the opportune administration of antibiotics, the costs associated with these conditions may be reduced.

As shown in table 3 and demonstrated in multiple randomized controlled trials, corticosteroids also have a significant impact on the reduction of the various conditions that may result as a consequence of PROM including: fetal and neonatal death, respiratory distress syndrome (RDS), intra-ventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), systemic infection within 48 hrs, and cerebral palsy (CP) [39]. The model depicted in table 3 illustrates real-life DRG payments for the various outcomes associated with PROM that corticosteroid administration can improve. As a more specific and detailed example related to table 3, the incidence of RDS in neonates

| Procedure                                | Percentage of Patients with Non-Obvious ROM Procedure is Used On | CPT®/HCPCS | 2011 Medicare Payment (per patient) |
|-------------------------------------------|------------------------------------------------------------------|------------|-----------------------------------|
| Speculum exam for ROM suspicion           | 100% [12]                                                       | CPT® 99218 [30,31] | $68.81                           |
| Ferring test                              | 100% [12]                                                       | CPT® 80114 [30,32] | $10.06                           |
| Vaginal pH/nitrazine test                 | 100% [12,24]                                                    | CPT® 83886QW [40,31] | $5.04                           |
| Ultrasound                                | 100% [12,24]                                                    | CPT® 76805 [33,34] | $149.84                          |
| Indigo carmine amnioinfusion             | 4.30% [24,29]                                                   | CPT® 59070 [35,36] | $13.72                           |
| Total cost per non-obvious ROM diagnosis |                                                                  |            | $247.47                          |

Table 1: Accuracies of Various ROM Methods in Non-Obvious Cases.
born to a mother with PROM who did not receive corticosteroids is 34% higher than the incidence of RDS in neonates born to a mother with PROM but who did receive a course of corticosteroids. Consequently, for all cases of PROM detected by the PAMG-1 test that would have been undetected by traditional methods (see sensitivities in table 1); a 34% reduction in the rate of RDS could be achieved.

By reducing the incidence of the various conditions associated with PROM through an accurate and timely diagnosis that allows for the appropriate intervention, the costs associated with these conditions should also be reduced.

**Costs of False Positive Diagnoses**

PROM occurs in 10% of all pregnancies with approximately 3% occurring during preterm gestations and the remaining 7% occurring at term. Therefore, close to 70% of patients diagnosed with PROM will have delivery induced and approximately 30% will be admitted into the hospital.

Aside from the administration of treatments previously described, two main pathways exist for managing patients diagnosed with PROM: (i) for patients at term or late pre-term (≥ 34 weeks of gestation), induction of labor is recommended and (ii) for patients at less than 34 weeks of gestation, hospitalization and observation is recommended to allow gestation to prolong [12]. Depending on the gestational age of a patient falsely diagnosed with PROM, one of these two pathways would be unnecessarily followed.

As figure 1 shows that, 2-22% of cases will be falsely diagnosed by using various combinations of traditional methodologies, 70% of these cases will be induced at a cost of $1,237.00 per induction [40], 17% of which will go on to have a C-section costing $11,092.00 [41]. The remaining 30% of falsely diagnosed patients with a gestational age less than or equal to 34 weeks, will almost certainly be hospitalized at a rate of $1,620.00/day [42]. As is often the case, these patients may spend multiple days in the hospital before a diagnosis is established and discharge can occur.

**Costs of Making ROM Diagnosis**

Table 2 outlines the costs associated with the various procedures available for diagnosing ROM. A review of the reimbursement amounts issued by the Centers for Medicare and Medicaid Services (CMS), even after adjusting for the incidence of some of the less prevalent methods (i.e., indigo carmine intra-amniotic injection), the costs of performing a diagnosis per patient via the typical combination of traditional methods remains greater than the costs of using the PAMG-1 test ($247.47 vs. $90.64). It should be noted that this model does not take into account the multiple iterations that each one of these methods may undergo during the full course of evaluation, which could significantly raise the cost of making the diagnosis by traditional methods.

**Conclusions**

In early 2011, the widespread use and clinical effectiveness of the fFN and PAMG-1 assays were formally recognized by the authors of the Guidelines for the Management of Spontaneous Preterm Labor in the Journal of Maternal-Fetal and Neonatal Medicine [43]. They stated that "The PAMG-1 immunoassay is the most useful tool in determining women at high risk for PROM" and that "Ultrasonography to determine cervical length, fFN testing, or a combination of both are the most useful tools in determining women at high risk for preterm labor".

Respected American organizations like the American Academy of Family Physicians [44] and guidelines like UptoDate [45] also mention the utility of the PAMG-1 assay in detecting PROM. Aside from improving quality and promoting evidence-based practice, payers benefit from the fFN and PAMG-1 tests because they directly translate
clinical advantages into potential cost reductions in the management of high risk patients.

The introduction of the fFN test into clinical practice preceded that of the PAMG-1 test by almost 10 years. Over this time, positive coverage determinations were issued by all major public and private payers on the use of the fFN test in the diagnosis of preterm labor (CPT® Code 82731; 1997) given its clinical utility and cost-effectiveness profile.

Similarly, PAMG-1, within the first few months of having been assigned a CPT® code (84112; 2011), has received positive coverage determinations by the majority of state Medicaid agencies and other private payers. Given the clinical and cost-effectiveness parallels that exist between the fFN test and the PAMG-1 test, it is expected that positive coverage for the PAMG-1 test will follow a similar path to that of the fFN test and evolve as the standard of care to improve diagnostic accuracy in ROM. In turn, this should reduce downstream costs through appropriate triage and management once an accurate diagnosis of PROM has been established.

References

1. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F et al. (2009) Births: Final Data for 2006. National Vital Statistics Reports 57: 1-104.
2. Society of Maternal Fetal Medicine (2010) “High-Risk Pregnancy Care, Research, and Education for Over 35 Years”.
3. Optum Health™ Claims Analysisin Leenay M (2011) Complex Medical Management for Medicaid Patients. AHP, Washington, DC.
4. St John EB, Nelson KG, Cliver SP, Bishnoi RR, Goldberg RL (2000) Cost of neonatal care according to gestational age at birth and survival status. Am J Obstet Gynecol 182: 170-175.
5. Sommers A, Cohen M (2006) Medicaid’s High Cost Enrollees: How Much Do They Drive Program Spending? Kaiser Commission on Medicaid and the Uninsured.
6. Crowther CA, Alfievic Z, Haslam RR (2010) Thryotropin-releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Database Syst Rev CD00019.
7. Hack M, Horbar JD, Malloy MH, Wright L, Tyson JE, et al. (1991) Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Network. Pediatrics 87: 587-597.
8. Keirse MJNC, Rush RW, Anderson AB, et al. (1978) Risk of preterm delivery and/or abortion. Br J Obstet Gynaecol 85: 81-85.
9. Goldberg RL, Culhane JF, Iams JD, Romero R (2008) Epidemiology and causes of preterm birth. Lancet 371: 75-84.
10. Iams JD, Casal D, McGregor JA, Goodwin TM, Kreaden US, et al. (1995) Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol 173: 141-145.
11. American College of Obstetricians and Gynecologists (2001) ACOG Practice Bulletin. Assessment of risk factors for preterm birth. Clinical management guidelines for obstetrician-gynecologists. Number 31, October 2001. (Replaces Technical Bulletin number 206, June 1995; Committee Opinion number 172, May 1996; Committee Opinion number 187, September 1997; Committee Opinion number 198, February 1998; and Committee Opinion number 251, January 2001). Obstet Gynecol 98: 708-716.
12. ACOG Committee on Practice Bulletins-Obstetrics (2007) ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol 109: 1007-1019.
13. Caughhey AB, Robinson JN, Norwitz ER (2008) Contemporary Diagnosis and Management of Preterm Premature Rupture of Membranes. Rev Obstet Gynecol 1: 11-22.
14. Feinberg RF, Kliman HJ, Lockwood CJ (1991) Is oncocetal fibronectin a trophoblast glue for human implantation? Am J Path 138: 537-543.
15. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/ deviceapprovalsandcleraneces/pmaapprovals/default.htm.
16. Iams JD, Casal D, McGregor JA, Goodwin TM, Kreaden US, et al. (1995) Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol 173: 141-145.
17. Joffe GM, Jacques D, Bermis-Heys R, Burton R, Skram B, et al. (1999) Impact of the fetal fibronectin assay on admissions for preterm labor. Am J Obstet Gynecol 180: 581-586.
18. Giles W, Bisits A, Knox M, Madsen G, Smith R (2000) The effect of fetal fibronectin testing on admissions to a tertiary maternal fetal medicine unit and cost savings. Am J Obstet Gynecol 182: 439-442.
19. El-Messadi A, Cameron A (2010) Diagnosis of premature rupture of membranes: inspiration from the past and insights for the future. J Obstet Gynaecol Can 32: 561-569.
20. Smith RP (1976) A technic for the detection of rupture of the membranes: a review and preliminary report. Obstet Gynecol. 48: 172-176.
21. Nisell H, Hagskog K, Westgren M (1986) Assessment of fetal fibronectin in cervical secretion in cases of equivocal rupture of the membranes at term. Acta Obstet Gynecol Scand. 75: 132-134.
22. Neil PRL, Wallace EM (2010) Is AmniSure® useful in the management of women with prelabour rupture of the membranes? Aust N Z J Obstet Gynaecol 50: 534-538.
23. Silva E, Martinez JC (2009) Diagnosing ROM: a comparison of the gold standard, indigo carmine amnioinfusion, to the rapid immunoassay, the AmniSure ROM test. J Perinat Med 37: 956.
24. BBirkmenmaier A, Ries JJ, Kuhle J, Bürki N, Lapaire O, Hösl ä I (2011) Placental alpha-microglobulin-1 to detect uncertain rupture of membranes in a European cohort of pregnancies. Arch Gynecol Obstet 285: 21-25.
25. de Haan HH, Offermans PM, Smits F, Schouten HJ, Peeters LL (1994) Value of the fern test to confirm or reject the diagnosis of ruptured membranes is modest in nonlaboring women presenting with nonspecific vaginal fluid loss.. Am J Perinatol 11: 46-50.
26. Jeurgens-Borst AJ, Beckers RL, Sporken JM, von den Berg PP (2002) Use of insulin like growth factor binding protein-1 in the diagnosis of ruptured fetal membranes. Eur J Obstet Gynecol Reprod Biol 102: 11-14.
27. Fujimoto S, Kishida T, Sagawa T, Negishi H, Okuyama K, et al. (1995) Clinical usefulness of the dye-injection method for diagnosing premature rupture of the membranes in equivocal cases. J Obstet Gynaecol (Tokyo) 1995: 21: 215-220.
28. Eriksen NL, Parisi VM, Daoust S, Flamm B, Garite TJ, et al. (1992) Fetal fibronectin: a method for detecting the presence of amniotic fluid. Obstet Gynecol 80: 451-454.
29. Lee SE, Park JS, Norwitz ER, Kim KW, Park HS, et al. (2007) Measurement of placental alpha-microglobulin-1 in cervicovaginal discharge to diagnose rupture of membranes. Obstet Gynecol 109: 634-640.
30. Center for Medicare & Medicaid Services, HHS. Tests Granted Waived Status under CLIA.
31. Center for Medicare & Medicaid Services, HHS. 2011 Clinical Lab Fee Schedule.
32. Find-A-Code.2011 HCPCS Q0114 (2011). Retrieved April 9, 2011.
33. Intermountain HealthCare, Ultrasound Content Standardization, Maternal Fetal Medicine.
34. Find-A-Code.2011 CPT 76805 (2011).
35. Society for Maternal Fetal Medicine. Fetal Surgery, 2004 new codes.
36. http://www.findacode.com/code.php?set= cpt &c=95070/.
37. Kenyon S, Bouvain M, Neilson J (2010) Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev 2: CD001058.
38. DRG Payment Schedule, Blue Cross Blue Shield of Massachusetts
39. Roberts D, Dalziel S (2010) Antenatal corticosteroids for accelerating fetal lung maturity for women at risk of preterm birth. Cochrane Database Syst Rev 2: CD004454.
40. Caughhey AB, Sundaram V, Kaimal AJ, et al. (2009) Maternal and Neonatal Outcomes of Elective Induction of Labor. Evidence Reports/Technology Assessments, No. 176.
41. Grant JM, Serie E, Mahmood T, Sarmandal P, Conway DI (1992) Management...
of prelabour rupture of the membranes in term primigravidae: report of a randomized prospective trial. Br J Obstet Gynaecol 99: 557-562.

42. http://healthcarebluebook.com/

43. Di Renzo GC, Roura LC, Facchinetti F, Antsaklis A, Breborowicz G, et al. (2011) Guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth. J Matern Fetal Neonatal Med. 24: 659-667.

44. Sayres W, Chapter D (2011) Preterm labor and premature rupture of membranes, AAFP-ALSO

45. Duff P, Lockwood C (2011) Diagnosis of Premature Rupture of Membranes.